912369-42-7Relevant articles and documents
INHIBITORS OF BRUTON'S TYROSINE KINASE
-
Paragraph 00765, (2016/12/22)
Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are describeded, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Synthesis and antiviral activity of 7-benzyl-4-hydroxy-1,5-naphthyridin- 2(1H)-one HIV integrase inhibitors
Boros, Eric E.,Edwards, Cynthia E.,Foster, Scott A.,Fuji, Masahiro,Fujiwara, Tamio,Garvey, Edward P.,Golden, Pamela L.,Hazen, Richard J.,Jeffrey, Jerry L.,Johns, Brian A.,Kawasuji, Takashi,Kiyama, Ryuichi,Koble, Cecilia S.,Kurose, Noriyuki,Miller, Wayne H.,Mote, Angela L.,Murai, Hitoshi,Sato, Akihiko,Thompson, James B.,Woodward, Mark C.,Yoshinaga, Tomokazu
experimental part, p. 2754 - 2761 (2010/01/16)
The medicinal chemistry and structure-activity relationships for a novel series of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV-integrase inhibitors are disclosed. Substituent effects were evaluated at the N-1, C-3, and 7-benzyl positions of the naph
SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS
-
, (2008/06/13)
This invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.